Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Phase 1

Completed

• Conditions: Multiple Myeloma; Lymphoma, Large B-Cell, Diffuse; Primary Central Nervous System Lymphoma; Glioblastoma; Pleiotropic Pathway Modifier; Lymphoma
• Interventions: Drug: CC-122

• Registration Number: NCT01421524
• Lead Sponsor: Celgene

Brief Summary

The main purpose of this first in human study with CC-122 is to assess the safety and action of a new class of experimental drug (Pleiotropic Pathway Modulator) in patients with advanced tumors unresponsive to standard therapies and to determine the appropriate dosing level and regimen for later-stage clinical trials.

Detailed Description

This trial is enrolling additional Multiple Myeloma (MM) subjects in a separate cohort defined as MM-2 to evaluate tolerability, safety and preliminary efficacy of CC-122 formulated capsule alone or in combination with DEX on intermittent dosing schedule (5 of 7 days of the week) in Pomalidomide-naïve subjects. Preliminary efficacy data in Multiple Myeloma subjects, warrants further exploration of CC-122 in MM on intermittent schedules to assess if dose intensity and tolerability can be improved. Initially, patients will be treated with oral CC-122 for one month. During this time, various tests (involving blood and urine collections, ECGs, etc) will be performed. Those whose tumors stabilize or regress may continue receiving treatment for as long as they benefit from CC-122. Different dose levels of CC-122 will be tested in a dose-rising study design.

Study Timeline

• Study First Submitted: 2011-08-19
• Study First Submitted QC: 2011-08-22
• Study First Posted: 2011-08-23
• Study Start: 2011-09-12
• Status Verified: 2023-11
• Primary Completion: 2023-11-21
• Study Completion: 2023-11-21
• Last Update Submitted: 2023-12-05
• Last Update Posted: 2023-12-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 271

Inclusion Criteria

1. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.

2. Men and women, 18 years or older, with histologically or cytologically-confirmed, advanced solid tumors, Non-Hodgkin Lymphona (NHL), Multiple Myloma (MM), or advanced unresectable solid tumors limited to the tumor types below.

   1. Subjects who have progressed on (or not been able to tolerate) standard anticancer therapy or for whom no standard anticancer therapy exists. Must have disease that is objectively measurable

   2. Measurable disease criteria:

      • Subjects with Glioblastoma multiforme (GBM) do not have to have objectively measurable disease at entry.
      • For MM, Diffuse large B-cell lymphoma (DLBCL): Subjects must have disease that is objectively measurable, measurable levels of myeloma paraprotein in serum (> 0.5 g/dL) or urine (> 0.2 g excreted in a 24-hour collection sample) for MM and measurable disease by Internatonal Working Group (IWG) for NHL (with at least one measurable lesion's longest diameter ≥ 2cm).
      • For Primary Central Nervous System (CNS) Lymphoma (PCNSL): Subjects must have disease that is objectively measurable by International Workshop to Standardize Baseline Evaluation and Response Criteria in Primary CNS Lymphoma, Cerebrospinal Fluid (CSF) cytology (in case of leptomeningeal only disease), or vitreal aspiration cytology and/or retinal photographs (in case of ocular lymphoma).

3. Tumor specific inclusion criteria:

   • DLBCL-2 cohort:

     • Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.
     • Histologically proven diffuse large B-cell non-Hodgkin's lymphoma
     • Must have progressed following or have been unable to tolerate at least one prior anthracycline or alkylating agent containing regimen (with or without anti-CD20).
     • Platelets ≥ 60 x 109/L.

   • For PCNSL cohort:

     • ECOG Performance Status of ≤ 2
     • Recurrent/refractory CNS non-Hodgkin's lymphoma involving CNS (Brain, Cerebrospinal fluid (CSF) or intraocular compartments)
     • Stable dose of glucocorticoids pre-therapy. If patients are receiving glucocorticoids, the dose should not increase during the 96 hours prior to initiation of therapy.
     • ECOG Performance Status of ≤ 2.

   • For glioblastoma multiforme (GBM-2) cohort:

     • ECOG Performance Status of ≤ 2
     • Primary GBM or gliosarcoma
     • ECOG Performance Status of ≤ 2.
     • Has received prior treatment including radiation and chemotherapy, with radiation completed > 12 weeks prior to Day 1 (or ≥ 4 weeks if the recurrence is outside of the prior radiation field).
     • Progression of disease after last therapy demonstrated by RANO criteria
     • No prior therapy with Avastin
     • No prior or scheduled Gliadel® wafer implant unless area of assessment and planned resection is outside the region previously implanted.
     • No prior interstitial brachytherapy or stereotactic radiosurgery unless area of assessment and planned resection is outside the region previously treated.
     • No enzyme-inducing anti-epileptic drugs (EIAED) such as carbamazepine, phenytoin, phenobarbital, or primidone within 14 days before Day 1.
     • Able to undergo repeated magnetic resonance imaging (magnetic resonance imaging (MRI), computed tomography (CT) scans).
     • Availability of adequate Formalin-fixed, paraffin embedded (FFPE) archival tumor material.
     • Platelets (plt) ≥ 100 x 109/L.

   • For Multiple Myeloma cohort

     • ECOG Performance Status of ≤ 1.
     • Have a documented diagnosis of multiple myeloma and have relapsed and refractory disease.

   • Measurable levels of myeloma paraprotein (M-protein) in serum (> 0.5 g/dL) or urine (> 0.2 g excreted in a 24-hour collection sample).

     • Patients must have received at least 2 prior therapies.
     • Patients must have relapsed after having achieved at least stable disease for at least one cycle of treatment to at least one prior regimen and then developed PD.
     • Patients must also have documented evidence of PD during or within 60 days (measured from the end of the last cycle) of completing treatment with the last anti-myeloma drug regimen used just prior to study entry (refractory disease).
     • Patients must have also undergone prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of a proteosome inhibitor (either in separate regimens or within the same regimen).
     • Must be Pomalidomide naïve.

   • Last dose of therapeutic glucocorticosteroids given greater than 14 days prior to start of study treatment.

   • Platelets (plt) ≥ 75 x 109/L in subjects in whom < 50% of bone marrow mononuclear cells are plasma cells or ≥ 30 x 109/L in subjects in whom ≥ 50% of bone marrow mononuclear cells are plasma cells.

4. At least 4 weeks from last dose of therapeutic glucocorticosteroids. Adrenal replacement doses of glucocorticosteroids (up to the equivalent of 10 mg daily prednisone) are allowed.

5. Biopsies (DLBLC, MM): Diagnostic archival FFPE (either in tumor blocks or sectioned/mounted specimens) may be submitted in lieu of a pre-study research biopsy if it has been obtained no more than 1 year prior to enrollment and only after discussion with the Celgene Medical Monitor

6. If not specified above as tumor specific parameter subjects must have the following laboratory and hematologic parameters as follows:

   1. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L without growth factor support for 7 days (14 days if received pegfilgrastim).
   2. Hemoglobin (Hgb) ≥ 9 g/dL.
   3. Platelets (Plt) ≥100 x 109/L.
   4. Potassium within normal limits or correctable with supplements.
   5. AST/SGOT and ALT/SGPT ≤ 3 x upper limit of normal (ULN) or ≤ 5.0 x ULN if liver tumor is present.
   6. Serum creatinine ≤ ULN (with value applied to Cockcroft-Gault equation) or 24 hour clearance ≥ 50mL/min.
   7. Negative serum pregnancy test in females of childbearing potential

Exclusion Criteria

1. History of other carcinomas within the last 5 years except cured non-melanoma skin cancer, curatively treated in-situ cervical cancer, or localized prostate cancer with a current Prostate-specific antigen (PSA) of <1.0 mg/dL on 2 evaluations at least 3 months apart; the most recent evaluation must be no more than 4 weeks prior to Day 1 of the study drug, or other malignancies that were completely resected or treated Stage 1/2 lesions currently in complete remission.

2. Symptomatic central nervous system metastases (excluding Glioblastoma multiforrme (GBM) and Primary Central Nervous System Lymphoma (PCNSL). Subjects with brain metastases that have been previously treated and are stable for 6 weeks are allowed.

3. Known symptomatic acute or chronic pancreatitis.

4. Any peripheral neuropathy ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade 2.

5. Persistent diarrhea or malabsorption ≥ NCI CTCAE grade 2, despite medical management.

6. Impaired cardiac function or clinically significant cardiac diseases, including any of the following:

   1. left ventricular ejection fraction (LVEF) < 45% as determined by multigated acquisition (MUGA) scan or echocardiography (ECHO).

   2. Complete left bundle branch, or bifasicular block.

   3. Congenital long QT syndrome.

   4. Persistent or uncontrolled ventricular arrhythmias or atrial fibrillation.

   5. QTcF > 460 msec on screening Electrocardiography (ECG) (mean of triplicate recordings).

   6. Unstable angina pectoris or myocardial infarction ≤ 3 months prior to starting CC-122.

   7. Troponin-T value > 0.4 ng/ml or BNP >300 pg/mL.

      ° Subjects with baseline troponin-T >Upper Limit of Normal (ULN) or B-type Natriuretic Peptide (BNP) >100 pg/mL are eligible but must have cardiologist evaluation prior to enrollment in the trial for baseline assessment and optimization of cardioprotective therapy.

   8. Other clinically significant heart disease such as congestive heart failure requiring treatment or uncontrolled hypertension (blood pressure ≥ 160/95 mmHg).

7. Other concurrent severe and/or uncontrolled concomitant medical conditions (eg, active or uncontrolled infection or renal disease) that could cause unacceptable safety risks or compromise compliance with the protocol.

8. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks, whichever is shorter, prior to starting study drug or who have not recovered from side effects of such therapy.

9. Major surgery ≤ 2 weeks prior to starting study drug or still recovering from post operative side effects.

10. Women who are pregnant or breast feeding. Adults of reproductive potential not employing two forms of birth control as per Pregnancy Prevention Risk Management Plan.

11. Known Human immunodeficiency virus (HIV) infection.

12. Known chronic hepatitis B or C virus (HBV/HCV) infection, unless comorbidity in subjects with Hepatocellular carcinoma (HCC).

13. Status post solid organ transplant.

14. Less than 100 days for subjects receiving autologous hematologic stem cell transplant (HSCT); or 6 months for subjects receiving allogenic HSCT or either transplant type, if otherwise not fully recovered from HSCT related toxicity.

15. For MM-2 cohort only: Hypersensitivity (eg, Rash Grade 3 or 4) to thalidomide, lenalidomide, or dexamethasone (MM-2b).

16. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.

17. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.

18. Any condition that confounds the ability to interpret data from the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CC-122 MM-2	CC-122	A new MM cohort (MM-2) will be enrolled in order to evaluate tolerability, safety and preliminary efficacy of the CC-122 formulated capsule given on an intermittent schedule (5/7 days per week) in 2 parallel dose escalation cohorts (MM-2a and MM-2b, respectively) (DEX) in Pomalidomide naïve subjects
Primary Central Nervous System Lymphoma (PCNSL)	CC-122	During dose expansion of selected intermittent schedules, an additional cohort of up to 10 subjects with PCNSL will also be explored at the same dose and schedule as DLBCL to confirm some safety and preliminary efficacy signal
CC-122- DLBCL-2	CC-122	A new DLBCL cohort (DLBCL-2) in order to evaluate intermittent schedules of CC-122 (5 continuous days out of 7 days per week \[5/7 days\] and/or 21 continuous days out of 28 days per cycle \[21/28 days\]). Doses to be explored include 4 mg and 5 mg on an intermittent schedule using the 3+3 design described in Part A in order to establish an MTD for the intermittent dosing schedules. Following dose escalation, one or more intermittent dosing schedules may be expanded at or below the new intermittent schedule MTD in at least 20 total subjects per dosing schedule.
CC-122- GBM-2	CC-122	A new GBM cohort (GBM-2) in order to evaluate doses of CC-122 above the 3 mg QD MTD determined in all comers in Part A. CC-122 dose will increase in 1 mg increments starting with 4 mg daily on a continuous schedule using the 3+3 design described in Part A in order to establish an MTD specific for GBM subjects. Following dose escalation, the cohort will be expanded at or below the new MTD in up to 20 total subjects.

Primary Outcome Measures

Name	Time	Method
Non-tolerated dose (NTD)	Up to day 28	Is defined as the dose level at which ≥2 out of 6 evaluable subjects in any dose cohort with DLT.
Pharmacokinetics- CL/F	Up to day 22	Apparent total body clearance
Pharmacokinetics- Vz/F	Up to day 22	Apparent volume of distribution
Maximum Tolerated Dose (MTD)	Up to day 28	Is defined as the last dose level below the NTD with ≤1 out of 6 evaluable subjects with DLT) during Cycle (C) 1.
Dose-Limiting Toxicity (DLT)	Up to approximately Day 28	Dose-limiting toxicities (DLTs) will be evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE): * A clinically relevant AE that is suspected to be related to CC-122 and starts ≤ 30 days of first dose (Cycle 1) and ≥ grade (Gr) 3 except for Alopecia, Gr3 rash of the acneiform or maculopapular type \< 4 daysduration , Gr 3 diarrhea or vomiting lasting\< 72 hours; * Clinically relevant laboratory abnormality suspected to be related to CC-122 and that commences within 30 days of first dose and ≥ Gr3.; * Hematological toxicities as follows: Any febrile neutropenia (NP), Gr4 NP \> 7 days, Gr 4 thrombocytopenia \> 24 hours, Any Gr 3/4 thrombocytopenia with clinically significant bleeding.; * Gr 4 liver function tests (LFTs) or Gr 3 ALT with ≥ Gr2 bilirubin; * Any AE suspected to be CC-122 related and necessitating dose reduction during Cycle 1.
Pharmacokinetics- Cmax	Up to day 22	Maximum observed concentration in plasma (Cmax)
Pharmacokinetics- AUC	Up to day 22	Area under the concentration-time curve
Pharmacokinetics- tmax	Up to day 22	Time to maximum concentration
Pharmacokinetics- t1/2	Up to day 22	Terminal half-life

Secondary Outcome Measures

Name	Time	Method
6-month progression free survival (PFS) rate for GBM chort	Up to approximately 6 months	The primary efficacy variable for GBM chohort is 6-month progression free survival (PFS).
Response Rate	up to approximately 6 months	The response rate of each tumor types based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1), International Workshop Criteria (IWC) for Non-Hodgkin's Lymphoma (NHL), International Uniform Response Criteria for Multiple Myeloma (IURC), or Responses Assessment for Neuro-Oncology (RANO) working group for Glioblastama multiforme (GBM)
Tissue concentration of CC-122	up to approximately 6 months	Tissue concentration of CC-122 in salvage resection specimens from subjects with GBM (CNS primary tumor) or in cerebrospinal fluid (CSF) from subjects undergoing lumbar puncture.

Trial Locations

Locations (39)

Rutgers Cancer Institute of New Jersey University; 🇺🇸 New Brunswick, New Jersey, United States

City of Hope Cancer Center; 🇺🇸 Duarte, California, United States

Texas Oncology, PA - Dallas 75246; 🇺🇸 Dallas, Texas, United States

Local Institution - 202; 🇫🇷 Caen Cedex, France

Local Institution - 105; 🇪🇸 Barcelona, Spain

Local Institution - 101; 🇪🇸 Barcelona, Spain

Local Institution - 201; 🇫🇷 Marseille le Cedex, France

Local Institution - 102; 🇪🇸 Madrid, Spain

Local Institution - 401; 🇧🇪 Bruxelles, Belgium

Local Institution - 400; 🇧🇪 Leuven, Belgium

Local Institution - 300; 🇮🇹 Milan, Italy

Local Institution - 020; 🇺🇸 New York, New York, United States

Local Institution - 203; 🇫🇷 Toulouse CEDEX 9, France

Local Institution - 200; 🇫🇷 Villejuif Cedex, France

Greenville Hospital System; 🇺🇸 Greenville, South Carolina, United States

Local Institution - 205; 🇫🇷 Pierre Bénite, France

Yakima Valley Memorial Hospital/ North Star Lodge; 🇺🇸 Yakima, Washington, United States

Local Institution - 108; 🇪🇸 Salamanca, Spain

Local Institution - 106; 🇪🇸 Pamplona, Spain

Local Institution - 303; 🇮🇹 Bologna, Italy

Local Institution - 104; 🇪🇸 Madrid, Spain

Local Institution - 103; 🇪🇸 Badalona (Barcelona), Spain

UCLA Neuro-Oncology Program; 🇺🇸 Los Angeles, California, United States

Swedish Medical Center Cancer Institute Research; 🇺🇸 Seattle, Washington, United States

Comprehensive Cancer Centers Of Nevada; 🇺🇸 Las Vegas, Nevada, United States

Local Institution - 305; 🇮🇹 Bologna, Italy

Local Institution - 302; 🇮🇹 Napoli, Campania, Italy

Mount Sinai Hospital; 🇺🇸 New York, New York, United States

Levine Cancer Institute; 🇺🇸 Charlotte, North Carolina, United States

Local Institution - 304; 🇮🇹 Roma, Italy

Local Institution - 301; 🇮🇹 Rozzano (MI), Italy

Local Institution - 107; 🇪🇸 Sevilla, Spain

Local Institution - 100; 🇪🇸 Valencia, Spain

UCSF Helen Diller Medical Center at Parnassus Heights; 🇺🇸 San Francisco, California, United States

University Of Michigan Comprehensive Cancer Center; 🇺🇸 Ann Arbor, Michigan, United States

Henry Ford Medical Center - New Center One; 🇺🇸 Detroit, Michigan, United States

MUSC Rheumatology and Immunology Dept.; 🇺🇸 Charleston, South Carolina, United States

Sarah Cannon Research Institute Drug Development Unit; 🇺🇸 Nashville, Tennessee, United States

South Texas Accelerated Research Therapeutics (START); 🇺🇸 San Antonio, Texas, United States